Theoretical Aspects of GPCR-Ligand Complex Pharmacology.
暂无分享,去创建一个
[1] T. Costa,et al. Agonist Efficacy and Aliosteric Models of Receptor Action a , 1997, Annals of the New York Academy of Sciences.
[2] T. Kenakin,et al. THE CUBIC TERNARY COMPLEX RECEPTOR-OCCUPANCY MODEL. II. UNDERSTANDING APPARENT AFFINITY , 1996 .
[3] Guodong Liu,et al. A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[4] R. Neubig,et al. Mechanism of agonist and antagonist binding to alpha 2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. , 1988, Biochemistry.
[5] C. Thron. On the analysis of pharmacological experiments in terms of an allosteric receptor model. , 1973, Molecular pharmacology.
[6] Lisa Nguyen,et al. Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.
[7] J. Giraldo,et al. On the fitting of binding data when receptor dimerization is suspected , 2008, British journal of pharmacology.
[8] M. Bouxsein,et al. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. , 2005, Endocrinology.
[9] Andrea Iaboni,et al. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.
[10] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[11] P. Gmeiner,et al. Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.
[12] D Rodbard,et al. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.
[13] L. Bohn,et al. Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[14] J N Langley,et al. On the Physiology of the Salivary Secretion , 1878, The Journal of physiology.
[15] Shailesh N Mistry,et al. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics , 2015, British journal of pharmacology.
[16] L. Potter,et al. Anti-muscarinic toxins from Dendroaspis angusticeps. , 1996, Toxicon : official journal of the International Society on Toxinology.
[17] Robyn L Stanfield,et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.
[18] J. Changeux,et al. On the excitability and cooperativity of the electroplax membrane. , 1968, Proceedings of the National Academy of Sciences of the United States of America.
[19] I. Charfi,et al. Identifying ligand‐specific signalling within biased responses: focus on δ opioid receptor ligands , 2015, British journal of pharmacology.
[20] B. Hudson,et al. Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands , 2014, Molecular Pharmacology.
[21] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[22] P. Sexton,et al. Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.
[23] B. Rovin,et al. The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .
[24] Bernard Katz,et al. Interaction at end-plate receptors between different choline derivatives , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.
[25] P. Wolynes,et al. The energy landscapes and motions of proteins. , 1991, Science.
[26] H. E. Umbarger,et al. Evidence for a negative-feedback mechanism in the biosynthesis of isoleucine. , 1956, Science.
[27] J. Black,et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation , 1985, British journal of pharmacology.
[28] B. Katz,et al. A study of the ‘desensitization’ produced by acetylcholine at the motor end‐plate , 1957, The Journal of physiology.
[29] A Herz,et al. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Ellis,et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[31] P. Molinoff,et al. Characterization of radiolabeled agonist binding to beta-adrenergic receptors in mammalian tissues. , 1980, Journal of cyclic nucleotide research.
[32] F. Ehlert. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. , 1985, Molecular pharmacology.
[33] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[34] H. Frauenfelder,et al. Conformational substates in proteins. , 1988, Annual review of biophysics and biophysical chemistry.
[35] A. Minarini,et al. Polymethylene tetraamines as muscarinic receptor probes. , 1989, Trends in pharmacological sciences.
[36] Arthur Christopoulos,et al. A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.
[37] Irving Langmuir. THE CONSTITUTION AND FUNDAMENTAL PROPERTIES OF SOLIDS AND LIQUIDS. PART I. SOLIDS. , 1916 .
[38] B. Roth,et al. Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds , 2014, Molecular Pharmacology.
[39] J. Changeux,et al. International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.
[40] M. Brann,et al. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. , 1991, Biochemical pharmacology.
[41] P. Sexton,et al. GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.
[42] T. Kenakin. New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.
[43] L. Johnson,et al. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. , 2000, Structure.
[44] T. Oas,et al. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] P. Sexton,et al. Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.
[46] M. Glass,et al. Allosteric Modulation of the Cannabinoid CB1 Receptor , 2017 .
[47] Vsevolod V Gurevich,et al. How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.
[48] Elliott M. Ross,et al. Signal sorting and amplification through G protein-coupled receptors , 1989, Neuron.
[49] J. M. Mathiesen,et al. Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.
[50] J P Changeux,et al. Ivermectin: A Positive Allosteric Effector of the α7 Neuronal Nicotinic Acetylcholine Receptor , 1998 .
[51] A. De Léan,et al. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland. , 1984, Molecular pharmacology.
[52] T. Kenakin. Collateral efficacy as a pharmacological problem applied to new drug discovery , 2006, Expert opinion on drug discovery.
[53] K. Mohr,et al. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors. , 1999, Molecular pharmacology.
[54] D. Koshland,et al. The active site and enzyme action. , 2006, Advances in enzymology and related subjects of biochemistry.
[55] A. Trkola,et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[56] Burgen As. Conformational changes and drug action. , 1981 .
[57] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[58] A Karlin,et al. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. , 1967, Journal of theoretical biology.
[59] R P STEPHENSON,et al. A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.
[60] G. Milligan,et al. The role of GPCR dimerisation/oligomerisation in receptor signalling. , 2006, Ernst Schering Foundation symposium proceedings.
[61] J. Dumont,et al. The two-step model of ligand-receptor interaction , 1977, Molecular and Cellular Endocrinology.
[62] I. Langmuir. THE CONSTITUTION AND FUNDAMENTAL PROPERTIES OF SOLIDS AND LIQUIDS , 1917 .
[63] R. Lefkowitz,et al. Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.
[64] Michel Bouvier,et al. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.
[65] N. Birdsall,et al. Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.
[66] J. Kemp,et al. A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.
[67] E. El-Fakahany,et al. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor. , 1992, The Journal of pharmacology and experimental therapeutics.
[68] R. Goody,et al. The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. , 2011, Biochemistry.
[69] Bryan L Roth,et al. Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors. , 2008, Biochemistry.
[70] C. Betsholtz,et al. Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. , 1994, Biochemical and biophysical research communications.
[71] T. Ramakrishnan,et al. Biosynthesis of isoleucine and valine in Mycobacterium tuberculosis H37 Rv. , 1968, Archives of biochemistry and biophysics.
[72] J. Olefsky,et al. β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells , 2008, Proceedings of the National Academy of Sciences.
[73] P. Cuatrecasas,et al. The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. , 1976, Biochimica et biophysica acta.
[74] Terry Kenakin,et al. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. , 2007, Trends in pharmacological sciences.
[75] A. Minton,et al. A model for the interaction of muscarinic receptors, agonists, and two distinct effector substances. , 1990, Biochemistry.
[76] T. Kenakin,et al. The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. , 1996, Journal of theoretical biology.
[77] T. Kenakin. The potential for selective pharmacological therapies through biased receptor signaling , 2012, BMC Pharmacology and Toxicology.
[78] M. Maguire,et al. Relationship between the beta-adrenergic receptor and adenylate cyclase. , 1977, The Journal of biological chemistry.
[79] C. Langmead,et al. Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia , 2011, Molecular Pharmacology.
[80] Laurence J. Miller,et al. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.
[81] N. Birdsall,et al. The binding of antagonists to brain muscarinic receptors. , 1978, Molecular pharmacology.
[82] David Colquhoun,et al. The Relation between Classical and Cooperative Models for Drug Action , 1973 .
[83] Clay W Scott,et al. Evaluating Cellular Impedance Assays for Detection of GPCR Pleiotropic Signaling and Functional Selectivity , 2009, Journal of biomolecular screening.
[84] G. Milligan. A day in the life of a G protein‐coupled receptor: the contribution to function of G protein‐coupled receptor dimerization , 2008, British journal of pharmacology.
[85] P. Morgan,et al. The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description , 1996 .
[86] D. Lauffenburger,et al. Epidermal growth factor receptor binding is not a simple one-step process. , 1989, The Journal of biological chemistry.
[87] H. Mitsuya,et al. Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.
[88] P. Cuatrecasas. Membrane receptors. , 1974, Annual review of biochemistry.
[89] P. Sexton,et al. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.
[90] J P Changeux,et al. On the cooperativity of biological membranes. , 1967, Proceedings of the National Academy of Sciences of the United States of America.
[91] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[92] F. Gasparini,et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.
[93] M. Caron,et al. Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides. , 1976, The Journal of biological chemistry.
[94] A. VanDongen,et al. G protein coupling of receptors to ionic channels and other effector systems. , 1990, British journal of clinical pharmacology.
[95] T. Kenakin,et al. The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.
[96] P. Casellas,et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.
[97] T. Kenakin,et al. The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? , 2009, Molecular Pharmacology.
[98] R. Iyengar,et al. Hormone receptor-mediated stimulation of adenylyl cyclase systems. Nucleotide effects and analysis in terms of a simple two-state model for the basic receptor-affected enzyme. , 1980, The Journal of biological chemistry.
[99] A. Scheer,et al. A Look at Receptor Efficacy. From the Signalling Network of the Cell to the Intramolecular Motion of the Receptor , 2000 .
[100] A. Maelicke,et al. New approach to drug therapy in Alzheimer's dementia Alfred Maelicke and Edson X. Albuquerque , 1996 .
[101] N. Shankley,et al. Interpretation of agonist affinity estimations: the question of distributed receptor states , 1990, Proceedings of the Royal Society of London. B. Biological Sciences.
[102] Y. Imai. Physiology of salivary secretion. , 1976, Frontiers of oral physiology.
[103] Liang Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002 .
[104] T. Oas,et al. A statistical thermodynamic model of the protein ensemble. , 2006, Chemical reviews.
[105] Michel Bouvier,et al. Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.
[106] F. Ciruela,et al. G‐protein‐coupled receptor heteromers: function and ligand pharmacology , 2008, British journal of pharmacology.
[107] P. Leff,et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.
[108] R. Lefkowitz,et al. A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.
[109] J. Galzi,et al. A novel, conformation‐specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[110] M. Maguire,et al. An agonist-specific effect of guanine nucleotides on binding to the beta adrenergic receptor. , 1976, Molecular pharmacology.
[111] Ariens Ej,et al. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. , 1954 .
[112] Jean Martinez,et al. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor , 2012, Proceedings of the National Academy of Sciences.
[113] T. Kenakin. Functional Selectivity and Biased Receptor Signaling , 2011, Journal of Pharmacology and Experimental Therapeutics.
[114] J. Gaddum. Theories of drug antagonism. , 1957, Pharmacological reviews.
[115] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[116] P. Tauber. Inhibition of lysosomal plasminogen activator activity in experimental shock. , 1973, Pharmacology.
[117] D. Mackay. Interpretation of relative potencies, relative efficacies and apparent affinity constants of agonist drugs estimated from concentration-response curves. , 1990, Journal of theoretical biology.
[118] R. Lefkowitz,et al. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.
[119] Thron Cd. On the analysis of pharmacological experiments in terms of an allosteric receptor model. , 1973 .
[120] E. Nisenbaum,et al. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. , 2004, Biochemical Society transactions.
[121] Frank McCormick,et al. The GTPase superfamily: a conserved switch for diverse cell functions , 1990, Nature.
[122] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[123] F. Ehlert. Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.
[124] H. Cheng,et al. Dissociation constants of D- and L-lactoylcholines and related compounds at cholinergic receptors. , 1972, The Journal of pharmacology and experimental therapeutics.
[125] R. Lefkowitz,et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.